FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3081006537> ?p ?o ?g. }

• W3081006537 endingPage "1265" @default.
• W3081006537 startingPage "1258" @default.
• W3081006537 abstract "BACKGROUND: Patients with hemophilia A are commonly treated with replacement recombinant factor VIII (rFVIII) products, which can be standard-acting or long-acting. Long-acting products have modifications, offering the potential for reduced dosing frequency while maintaining therapeutic benefit. Extended dosing intervals reduce patient burden and can improve quality of life and adherence. OBJECTIVE: To assess real-world data for the use of 6 commonly prescribed standard-acting and long-acting FVIII products in the United States: octocog alfa, BAY 14-2222, BAY 81-8973, rVIII-SingleChain, rFVIIIFc, and polyethylene glycol (PEG)-rFVIII. We summarized annualized bleeding rates (ABRs), dosing frequency, and factor consumption in patients treated with each product, with subgroup analyses for patients with severe disease. METHODS: De-identified patient data were collected from 11 hemophilia treatment centers in the United States. Patients treated with octocog alfa, BAY 14-2222, BAY 81-8973, rVIII-SingleChain, rFVIIIFc, or PEG-rFVIII prophylaxis for ≥ 8 weeks at the time of data collection were included in the analysis. Among the 6 treatment groups, matching was attempted for patient age and disease severity where possible. RESULTS: Data were obtained for 240 patients, of whom 191 patients had severe disease. Patients receiving long-acting FVIII products were dosed less frequently than those receiving standard-acting FVIII products. The proportion of patients dosed 2 times weekly or less was 65.0%, 70.0%, 72.5%, 25.0%, 40.0%, and 47.5% with rVIII-SingleChain, rFVIIIFc, PEG-rFVIII, octocog alfa, BAY 14-2222, and BAY 81-8973, respectively. Median ABRs ranged from 2.0 to 3.0 (mean 2.6 to 4.4) across the 6 products for all patients and were similar for patients with severe disease (median 2.0 to 3.0 and mean 2.5 to 4.8). The proportion of patients experiencing 0 bleeding episodes ranged from 7.5% to 25.0% for all patients and 12.0% to 28.6% for patients with severe disease. For all patients, median (mean) weekly FVIII product consumption was lowest for rVIII-SingleChain among the 6 products (P = 0.045); 91.9 (91.1) IU per kg per week for rVIII-SingleChain, 108.5 (103.6) for rFVIIIFc, 97.6 (111.0) for PEG-rFVIII, 114.0 (117.5) for octocog alfa, 102.5 (102.6) for BAY 14-2222, and 95.1 (100.7) for BAY 81-8973. Similar differences in weekly consumption among the 6 products were observed for patients with severe disease (P = 0.014). CONCLUSIONS: Real-world data demonstrate that long-acting products may be beneficial compared with standard-acting products because of reduced dosing frequency while maintaining effectiveness. The 6 products evaluated showed statistically comparable ABRs and percentage of patients with 0 bleeds for all patients including those with severe disease. rVIII-SingleChain demonstrated lowest mean consumption for all patients, as well as for patients with severe hemophilia A, which may lead to potential savings in health care costs. DISCLOSURES: This study was funded by CSL Behring. Simpson reports consulting honoraria for participation in advisory boards for Bayer, CSL Behring, HEMA Biologics, Novo Nordisk, Octapharma, and Takeda and speakers bureau for Bayer and Novo Nordisk. Yan and Desai are employees of CSL Behring. Maro is an employee of Adivo Associates, which conducted the analyses for this study. Data were presented in part at the Hemostasis and Thrombosis Research Society; May 9-11, 2019; New Orleans, LA; at the International Society on Thrombosis and Haemostasis; July 6-10, 2019; Melbourne, Australia; and have been published in part in “Comparing Factor Use and Bleed Rates in U.S. Hemophilia A Patients Receiving Prophylaxis with 3 Different Long-Acting Recombinant Factor VIII Products,” by Mindy L. Simpson, Vidhi Desai, Géraldine S. Maro, Songkai Yan (J Manag Care Spec Pharm. 2020;26[4]:504-12)." @default.
• W3081006537 created "2020-09-01" @default.
• W3081006537 creator A5000709073 @default.
• W3081006537 creator A5011063268 @default.
• W3081006537 creator A5031696129 @default.
• W3081006537 creator A5069298451 @default.
• W3081006537 date "2020-10-01" @default.
• W3081006537 modified "2023-09-26" @default.
• W3081006537 title "A Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients" @default.
• W3081006537 cites W1521912671 @default.
• W3081006537 cites W1623696825 @default.
• W3081006537 cites W1974965024 @default.
• W3081006537 cites W2013607072 @default.
• W3081006537 cites W2024830476 @default.
• W3081006537 cites W2026502021 @default.
• W3081006537 cites W2063255503 @default.
• W3081006537 cites W2089040795 @default.
• W3081006537 cites W2212870307 @default.
• W3081006537 cites W2472001395 @default.
• W3081006537 cites W2529483216 @default.
• W3081006537 cites W2558231086 @default.
• W3081006537 cites W2626664330 @default.
• W3081006537 cites W2760631163 @default.
• W3081006537 cites W2766206296 @default.
• W3081006537 cites W2787721065 @default.
• W3081006537 cites W2793409309 @default.
• W3081006537 cites W2805945157 @default.
• W3081006537 cites W2891041376 @default.
• W3081006537 cites W2995564136 @default.
• W3081006537 cites W2998151408 @default.
• W3081006537 cites W3005162225 @default.
• W3081006537 doi "https://doi.org/10.18553/jmcp.2020.20199" @default.
• W3081006537 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32820685" @default.
• W3081006537 hasPublicationYear "2020" @default.
• W3081006537 type Work @default.
• W3081006537 sameAs 3081006537 @default.
• W3081006537 citedByCount "11" @default.
• W3081006537 countsByYear W30810065372021 @default.
• W3081006537 countsByYear W30810065372022 @default.
• W3081006537 countsByYear W30810065372023 @default.
• W3081006537 crossrefType "journal-article" @default.
• W3081006537 hasAuthorship W3081006537A5000709073 @default.
• W3081006537 hasAuthorship W3081006537A5011063268 @default.
• W3081006537 hasAuthorship W3081006537A5031696129 @default.
• W3081006537 hasAuthorship W3081006537A5069298451 @default.
• W3081006537 hasBestOaLocation W30810065371 @default.
• W3081006537 hasConcept C115880899 @default.
• W3081006537 hasConcept C126322002 @default.
• W3081006537 hasConcept C127413603 @default.
• W3081006537 hasConcept C147176958 @default.
• W3081006537 hasConcept C194828623 @default.
• W3081006537 hasConcept C2777288759 @default.
• W3081006537 hasConcept C71924100 @default.
• W3081006537 hasConceptScore W3081006537C115880899 @default.
• W3081006537 hasConceptScore W3081006537C126322002 @default.
• W3081006537 hasConceptScore W3081006537C127413603 @default.
• W3081006537 hasConceptScore W3081006537C147176958 @default.
• W3081006537 hasConceptScore W3081006537C194828623 @default.
• W3081006537 hasConceptScore W3081006537C2777288759 @default.
• W3081006537 hasConceptScore W3081006537C71924100 @default.
• W3081006537 hasIssue "10" @default.
• W3081006537 hasLocation W30810065371 @default.
• W3081006537 hasLocation W30810065372 @default.
• W3081006537 hasOpenAccess W3081006537 @default.
• W3081006537 hasPrimaryLocation W30810065371 @default.
• W3081006537 hasRelatedWork W159247329 @default.
• W3081006537 hasRelatedWork W2025193597 @default.
• W3081006537 hasRelatedWork W2026095104 @default.
• W3081006537 hasRelatedWork W2042489430 @default.
• W3081006537 hasRelatedWork W2083479052 @default.
• W3081006537 hasRelatedWork W2115778339 @default.
• W3081006537 hasRelatedWork W2153810843 @default.
• W3081006537 hasRelatedWork W2165432975 @default.
• W3081006537 hasRelatedWork W2626766173 @default.
• W3081006537 hasRelatedWork W2947337648 @default.
• W3081006537 hasVolume "26" @default.
• W3081006537 isParatext "false" @default.
• W3081006537 isRetracted "false" @default.
• W3081006537 magId "3081006537" @default.
• W3081006537 workType "article" @default.